Steven Kelly
Before Theracrine, Kelly was the chief commercial officer for oncolytic virus specialists BioVex, and was responsible for leading the company's commercial efforts.
David Berry, founder and chairman of the firm, said: “Theracrine is breaking new ground as it develops the next generation of cancer therapeutics.
“Steve's experience in bringing previous generations of breakthrough cancer drugs to market makes him an ideal fit to lead the company.”